Essential dermatitis

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

Retrieved on: 
Thursday, February 11, 2021
Medical specialties, Atopic dermatitis, Type I hypersensitivity, Immunology, Dermatitis, Clinical medicine, Eczema, Essential dermatitis, Dog skin disorders

LONDON, Feb. 11, 2021 /PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

Key Points: 
  • LONDON, Feb. 11, 2021 /PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.
  • Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin.
  • BEN-2293 is positioned to address both the inflammation and itch associated with Atopic Dermatitis in both adults and children, representing a comprehensive, new treatment available for a broad patient population.
  • Anne Phelan, Chief Scientific Officer at BenevolentAI, commented, "The poor treatment options available for Atopic Dermatitis patients make the disease difficult to endure.

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

Retrieved on: 
Thursday, February 11, 2021
Medical specialties, Atopic dermatitis, Type I hypersensitivity, Immunology, Dermatitis, Clinical medicine, Eczema, Essential dermatitis, Dog skin disorders

LONDON, Feb. 11, 2021 /PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

Key Points: 
  • LONDON, Feb. 11, 2021 /PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.
  • Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin.
  • BEN-2293 is positioned to address both the inflammation and itch associated with Atopic Dermatitis in both adults and children, representing a comprehensive, new treatment available for a broad patient population.
  • Anne Phelan, Chief Scientific Officer at BenevolentAI, commented, "The poor treatment options available for Atopic Dermatitis patients make the disease difficult to endure.

Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones

Retrieved on: 
Thursday, January 7, 2021
Type I hypersensitivity, Medical specialties, Immunology, Atopic dermatitis, Dermatitis, Atopy, Clinical medicine, Essential dermatitis, Sodium hypochlorite washes

We reported positive clinical data for EDP1815 in both atopic dermatitis and a human experimental model of inflammation, showing translation of preclinical results into humans.

Key Points: 
  • We reported positive clinical data for EDP1815 in both atopic dermatitis and a human experimental model of inflammation, showing translation of preclinical results into humans.
  • In parallel, we invested in manufacturing capabilities and supply chain to advance our ability to deliver our products at commercial scale.
  • Atopic dermatitis is the most common chronic skin disease, impacting an estimated 10% of adults and 25% of children globally.
  • Generating initial clinical data on the safety and pharmacology of the Companys next anti-inflammatory product candidate, EDP1867, in atopic dermatitis.

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

Retrieved on: 
Sunday, April 5, 2020
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, RTT, Organic compounds, Medical specialties, Cyclopentanes, Nitriles, Pyrazoles, Ruxolitinib, Dermatitis, Atopic dermatitis, Essential dermatitis

Incyte (Nasdaq: INCY) today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium.
  • Data that will be presented today during the Revolutionizing Atopic Dermatitis Virtual Symposium show that ruxolitinib cream significantly reduced both the skin inflammation and itch associated with atopic dermatitis.
  • The overall safety profile of ruxolitinib cream in atopic dermatitis was consistent with previous study data, with no new safety signals observed.
  • The potential of ruxolitinib cream to become an important treatment option for patients living with atopic dermatitis is exciting.